<DOC>
	<DOCNO>NCT00618774</DOCNO>
	<brief_summary>To assess long term safety efficacy telmisartan plus amlodipine FDC patient essential hypertension fail control BP either monotherapy</brief_summary>
	<brief_title>An Open-label , Long-term Study Telmisartan Plus Amlodipine Fixed-dose Combination</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1 . Patients essential hypertension 2 . Outpatient Patients whose SBP &gt; =180 mmHg DBP &gt; =110 mmHg end treatment visit doubleblind treatment period `` nonresponder trial '' Patients meet exclusion criterion define `` nonresponder trial ''</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>